NCT03115255View on ClinicalTrials.gov

Serum Vascular Endothelial Growth Factor in Infants With Intravitreal Ranibizumab

NACompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 1, 2017

Primary Completion Date

May 31, 2018

Study Completion Date

June 30, 2018

Conditions
Infant, Premature, Diseases
Interventions
DRUG

intravitreal ranibizumab

0.25 mg intravitreal ranibizumab to either 1 eye (unilateral cases) or both eyes (bilateral cases)

Trial Locations (1)

200092

Xinhua Hospital, Shanghai

All Listed Sponsors
lead

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT03115255 - Serum Vascular Endothelial Growth Factor in Infants With Intravitreal Ranibizumab | Biotech Hunter | Biotech Hunter